About: Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19
Creator	Albillos, Agustín Barreales, Mónica Bañares, Rafael Bighelli, Federico Caballero, Aránzazu Calleja, José Caravaca, Celia Carrillo, Carlos Fernández, Inmaculada García-Samaniego, Javier Ibáñez-Samaniego, Luis Madejón, Antonio Perelló, Christie Romero, Miriam Usón, Clara
source	Medline; PMC
abstract	BACKGROUND: COVID-19 is a potentially severe disease caused by the recently described SARS-CoV-2. Whether liver fibrosis might be a relevant player in the natural history of COVID-19 is currently unknown. We aimed to evaluate the association between FIB-4 and the risk of progression to critical illness in middle-aged patients with COVID-19. METHODS: In this multicenter, retrospective study with prospective follow-up of 160 patients aged 35–65 years with COVID-19, FIB-4, clinical, and biochemical variables were collected at baseline. FIB-4 ≥2.67 defined patients with risk for advanced liver fibrosis. RESULTS: Risk for advanced fibrosis was estimated in 28.1% of patients. Patients with FIB-4 ≥2.67 more frequently required mechanical ventilation (37.8% vs 18.3%; P = .009). In multivariate analysis, FIB-4 ≥2.67 (odds ratio [OR], 3.41; 95% confidence interval [CI], 1.30–8.92), cardiovascular risk factors (OR, 5.05; 95% CI, 1.90–13.39), previous respiratory diseases (OR, 4.54; 95% CI, 1.36–15.10), and C-reactive protein (OR, 1.01; 95% CI, 1.01–1.02) increased significantly the risk of ICU admission. Bootstrap confirmed FIB-4 as an independent risk factor. CONCLUSIONS: In middle-aged patients with COVID-19, FIB-4 may have a prognostic role. The link between liver fibrosis and the natural history of COVID-19 should be evaluated in future studies.
has issue date	2020-06-21(xsd:dateTime)
bibo:doi	10.1093/infdis/jiaa355
bibo:pmid	32563190
has license	no-cc
sha1sum (hex)	67fcd78417ae0b1daaa28b42393896afb642a585
schema:url	https://doi.org/10.1093/infdis/jiaa355
resource representing a document's title	Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19
has PubMed Central identifier	PMC7337860
has PubMed identifier	32563190
schema:publication	J Infect Dis
resource representing a document's body	covid:67fcd78417ae0b1daaa28b42393896afb642a585#body_text
is schema:about of	named entity 'COVID-19' named entity 'Patients' named entity 'With' named entity 'mechanical ventilation' named entity 'liver' named entity 'fibrosis' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'platelet' named entity 'elastography' named entity 'primary care' named entity 'COVID-19' named entity 'COVID' named entity 'general population' named entity 'ferritin' named entity 'chronic liver disease' named entity 'biochemical' named entity 'immune cells' named entity 'elastography' named entity 'Odds ratios' named entity 'blood test' named entity 'hyperbilirubinemia' named entity 'AST' named entity 'liver' named entity 'advanced liver disease' named entity 'fibrosis' named entity 'insulin resistance' named entity 'liver fibrosis' named entity 'fibrosis' named entity 'IL-6' named entity 'Fisher exact test' named entity 'COVID-19' named entity 'AST' named entity 'risk factors' named entity 'ARDS' named entity 'western countries' named entity 'Noninvasive' named entity 'multivariate analyses' named entity 'COVID' named entity 'steatosis' named entity 'blood tests' named entity 'hepatocyte' named entity 'aspartate aminotransferase' named entity 'cirrhosis' named entity 'liver disease' named entity '2, 3' named entity 'liver failure' named entity 'cardiovascular disease' named entity 'liver fibrosis' named entity 'fibrosis' named entity 'liver diseases' named entity 'logistic regression' named entity 'fibrosis' named entity 'CRP' named entity 'platelets' named entity 'type 2 diabetes mellitus' named entity 'valvular heart disease' named entity 'myopathies' named entity 'renal diseases' named entity 'liver fibrosis' named entity 'damage-associated molecular patterns' named entity 'intracerebral hemorrhage' named entity 'multivariate analysis' named entity 'hypopnea' named entity 'IL-6' named entity 'hepatocyte' named entity 'atrial fibrillation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software